Maintenance of differential methotrexate toxicity between cells expressing drug-resistant and wild-type dihydrofolate reductase activities in the presence of nucleosides through nucleoside transport inhibition

Biochemical Pharmacology

Volumn 59, Issue 2, 2000, Pages 141-151

  Warlick, Christopher A ^a   Sweeney, Colin L ^a   McIvor, R Scott ^a  

^a Institute of Human Genetics   (United States)

Author keywords

Chemotherapy; Dihydrofolate reductase; Dipyridamole; Drug resistance; Methotrexate; Nucleoside transport inhibitors

Indexed keywords

ANTIINFECTIVE AGENT; DIHYDROFOLATE REDUCTASE; DIPYRIDAMOLE; METHOTREXATE; NUCLEOSIDE; THYMIDINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN K 562; CONTROLLED STUDY; DRUG RESISTANCE; DRUG TOXICITY; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL;

3T3 CELLS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARRIER PROTEINS; DIPYRIDAMOLE; DRUG RESISTANCE, NEOPLASM; HUMANS; K562 CELLS; MEMBRANE PROTEINS; METHOTREXATE; MICE; NUCLEOSIDE TRANSPORT PROTEINS; NUCLEOSIDES; PHOSPHODIESTERASE INHIBITORS; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 0033990959     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00311-1     Document Type: Article

References (59)

1. 31 substitutions . J Biol Chem. 269:1994;9547-9555.
2. Simonsen C.C., Levinson A.D. Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc Natl Acad Sci USA. 80:1983;2495-2499.
3. McIvor R.S., Simonsen C. Isolation and characterization of a variant dihydrofolate reductase cDNA from methotrexate-resistant murine L5178Y cells. Nucleic Acids Res. 18:1990;7025-7032.
4. Braun S.E., McIvor R.S., Davidson A.S., Hanna M., Traycoff C.M., Berebetsky D.A., Gonin R., Broxmeyer H.E., Cornetta K. Retrovirally mediated gene transfer of Arg22 and Tyr22 forms of dihydrofolate reductase into the hematopoietic cell line K562 A comparison of methotrexate resistance . Cancer Gene Ther. 4:1997;26-32.
5. May C., Gunther R., McIvor R.S. Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity. Blood. 86:1995;2439-2448.
6. Williams D.A., Hsieh K., DeSilva A., Mulligan R.C. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J Exp Med. 166:1987;210-218.
7. Corey C.A., DeSilva A.D., Holland C.A., Williams D.A. Serial transplantation of methotrexate-resistant bone marrow Protection of murine recipients from drug toxicity by progeny of transduced stem cells . Blood. 75:1990;337-343.
8. Zhao S.C., Li M.X., Banerjee D., Schweitzer B.I., Mineishi S., Gilboa E., Bertino J.R. Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double copy vector retrovirus containing a mutant dihydrofolate reductase. Cancer Gene Ther. 1:1994;27-33.
9. James R.I., May C., Vagt M.D., Studebaker R., McIvor R.S. Transgenic mice expressing the tyr22 variant of murine DHFR Protection of transgenic marrow transplant recipients from lethal doses of methotrexate . Exp Hematol. 25:1997;1286-1295.
10. Spencer H.T., Sleep S.E., Rehg J.E., Blakley R.L., Sorrentino B.P. A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood. 87:1996;2579-2587.
11. Sur P., Matsuo Y., Otani T., Minowada J. Reversal of methotrexate-induced folate pool depletion by thymidine in a human leukemia cell line in vitro. Tumori. 79:1993;433-438.
12. Zhen Y.S., Lui M.S., Weber G. Effects of acivicin and dipyridamole on hepatoma 3924A cells. Cancer Res. 43:1983;1616-1619.
13. Nelson J.A., Drake S. Potentiation of methotrexate toxicity by dipyridamole. Cancer Res. 44:1984;2493-2496.
14. Cabral S., Leis S., Bover L., Nembrot M., Mordoh J. Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells. Proc Natl Acad Sci USA. 81:1984;3200-3203.
15. Plagemann P.G.W., Wohlhueter R.M. Effects of nucleoside transport inhibitors on the salvage and toxicity of adenosine and deoxyadenosine in L1210 and P388 mouse leukemia cells. Cancer Res. 45:1985;6418-6424.
16. Su J., Zhen Y., Qi C., Hu J. Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs. Cancer Chemother Pharmacol. 36:1995;149-154.
17. Grem J.L., Fischer P.H. Enhancement of 5-fluorouracil's anticancer activity by dipyridamole. Pharmacol Ther. 40:1989;349-371.
18. Goel R., Cleary S.M., Horton C., Balis F.M., Zimm S., Kirmani S., Howell S.B. Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole. J Clin Oncol. 7:1989;262-269.
19. Wei C.M., Gibson M., Spear P.G., Scolnick E.M. Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1. J Virol. 39:1981;935-944.
20. Markowitz D., Goff S., Bank A. A safe packaging line for gene transfer Separating viral genes on two different plasmids . J Virol. 62:1988;1120-1124.
21. Miller A.D., Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol. 6:1986;2895-2902.
22. Pugh J.C., Yaginuma K., Koike K., Summers J. Duck hepatitis B virus (DHBV) particles produced by transient expression of DHBV DNA in a human hepatoma cell line are infectious in vitro. J Virol. 62:1988;3513-3516.
23. Lozzio C.B., Lozzio B.B. Cytotoxicity of a factor isolated from human spleen. J Natl Cancer Inst. 50:1973;535-538.
24. Lozzio B.B., Lozzio C.B. Properties of the K562 cell line derived from a patient with chronic myeloid leukemia. Int J Cancer. 19:1977;136.
25. Maniatis T., Fritsch E.F., Sambrook J. Molecular Cloning A Laboratory Manual . 1982;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
26. Graham F.L., van der Eb A.J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 52:1973;456-457.
27. Miller A.D., Rosman G.J. Improved retroviral vectors for gene transfer and expression. Biotechniques. 7:1989;980-982.
28. Vinh D.B.N., McIvor R.S. Selective expression of methotrexate-resistant dihydrofolate reductase (DHFR) activity in mice transduced with DHFR retrovirus and administered methotrexate. J Pharmacol Exp Ther. 267:1993;989-996.
29. Jonsson J.J., Habel D.E., McIvor R.S. Retrovirus-mediated transduction of an engineered intron-containing purine nucleoside phosphorylase gene. Hum Gene Ther. 6:1995;611-623.
30. Morris J.A., McIvor R.S. Saturation mutagenesis at dihydrofolate reductase codons 22 and 31. A variety of amino acid substitutions conferring methotrexate resistance. Biochem Pharmacol. 47:1994;1207-1220.
31. Haber D.A., Beverley S.M., Kiely M.L., Schimke R.T. Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts. J Biol Chem. 256:1981;9501-9510.
32. Hakala M.T., Taylor E. The ability of purine and thymidine derivatives and of glycine to support the growth of mammalian cells in culture. J Biol Chem. 234:1959;126-128.
33. Samuels L.L., Straw J.A. Improved therapeutic index with high-dose methotrexate Comparison of thymidine-purine rescue with citrovorum factor rescue in mice . Cancer Res. 44:1984;2278-2284.
34. Dady P.J., Taylor G.A., Muindi J.F., Calvert A.H., Smith I.E., Smyth J.F., Harrap K.R. Methotrexate with thymidine, inosine, and allopurinol rescue A phase I clinical study . Cancer Treat Rep. 65:(Suppl 1):1981;37-43.
35. Howell S.B., Herbst K., Boss G.R., Frei E. III. Thymidine requirements for rescue of patients treated with high-dose methotrexate. Cancer Res. 40:1980;1824-1829.
36. Van Mouwerik T.J., Pangallo C.A., Wilson J.K., Fischer P.H. Augmentation of methotrexate cytotoxicity in human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole. Biochem Pharmacol. 36:1987;809-814.
37. Cao S., Zhen Y. Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol. 24:1989;181-186.
38. Allay J.A., Spencer H.T., Wilkinson S.L., Belt J.A., Blakley R.L., Sorrentino B.P. Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood. 90:1997;3546-3554.
39. Allay J.A., Persons D.A., Galipeau J., Riberdy J.M., Ashmun R.A., Blakley R.L., Sorrentino B.P. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med. 4:1998;1136-1143.
40. Hughes W.L., Christine M., Stollar D. A radioimmunoassay for measurement of serum thymidine. Anal Biochem. 55:1973;468-478.
41. Nottebrock H., Then R. Thymidine concentrations in serum and urine of different animal species and man. Biochem Pharmacol. 26:1977;2175-2179.
42. Radparvar S., Houghton P.J., Germain G., Pennington J., Rahman A., Houghton J.A. Cellular pharmacology of 5-flourouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiency. Biochem Pharmacol. 39:1990;1759-1765.
43. Levine R.L., Hoogenraad N.J., Kretchmer N. A review Biological and clinical aspects of pyrimidine metabolism . Pediat Res. 8:1974;724-734.
44. Lajtha L.G., Vane J.R. Dependence of bone marrow cells on the liver for purine supply. Nature. 182:1958;191-192.
45. Fox I.H., Kelley W.N. The role of adenosine and 2′-deoxyadenosine in mammalian cells. Annu Rev Biochem. 47:1978;655-686.
46. Murray A.W. The biological significance of purine salvage. Annu Rev Biochem. 40:1971;811-826.
47. Griffith D.A., Jarvis S.M. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta. 1286:1996;153-181.
48. Crawford C.R., Patel D.H., Naeve C., Belt J.A. Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. J Biol Chem. 273:1998;5288-5293.
49. Griffiths M., Beaumont N., Yao S.Y., Sundaram M., Boumah C.E., Davies A., Kwong F.Y., Coe I., Cass C.E., Young J.D., Baldwin S.A. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med. 3:1997;89-93.
50. Crawford C., Patel D., Belt J. Isolation of a human cDNA that confers equilibrative, nitrobenzylmercaptopurine riboside-insensitive nucleoside transport activity (ei) to a transport deficient human leukemia cell line. Proc Am Assoc Cancer Res. 38:1997;60.
51. +-nucleoside cotransporter. J Biol Chem. 270:1995;13596-13599.
52. Huang Q.Q., Yao S.Y., Ritzel M.W., Paterson A.R., Cass C.E., Young J.D. Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein. J Biol Chem. 269:1994;17757-17760.
53. Mackey J.R., Baldwin S.A., Young J.D., Cass C.E. Nucleoside transport and its significance for anticancer drug resistance. Drug Resistance Updates. 1:1998;310-324.
54. Jennings L.L., Cass C.E., Ritzel M.W.L., Yao S.Y.M., Young J.D., Griffiths M., Baldwin S.A. Adenosine transport Recent advances in the molecular biology of nucleoside transporter proteins . Drug Dev Res. 45:1998;277-287.
55. Boleti H., Coe I.R., Baldwin S.A., Young J.D., Cass C.E. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacology. 36:1997;1167-1179.
56. Evenson D.A., Adams J., McIvor R.S., Wagner C.R. Methotrexate resistance of mouse dihydrofolate reductase Effect of substitution of phenylalanine-31 by serine or tryptophan . J Med Chem. 39:1996;1763-1766.
57. Morris J.A., May C., Kim H.S., Ismail R., Wagner J.E., Gunther R., McIvor R.S. Comparative methotrexate resistance of transgenic mice expressing two distinct dihydrofolate reductase variants. Transgenics. 2:1996;53-67.
58. Isola L.M., Gordon J.W. Systemic resistance to methotrexate in transgenic mice carrying a mutant dihydrofolate reductase gene. Proc Natl Acad Sci USA. 83:1986;9621-9625.
59. Dunbar C.E., Young N.S. Gene marking and gene therapy directed at primary hematopoietic cells. Curr Opin Hematol. 3:1996;430-437.